(PSNL) Personalis, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PSNL) Personalis, Inc. Complete Analysis Pack
Personalis Business Model: Genomics, Strategy, Growth
Discover how Personalis, Inc. turns precision genomics into a focused business strategy. This Business Model Canvas breaks down its key partners, value proposition, revenue logic, and cost drivers in a clear, practical format. Get the full version to uncover the strategic details behind the company’s growth and competitive edge.
Partnerships
Mayo Clinic collaboration
Personalis’s named Mayo Clinic collaboration supports translational cancer research and clinical validation of its sequencing workflows. Mayo Clinic is one of the largest U.S. academic medical centers, with more than 5 million patient visits a year, so the tie-up gives Personalis access to strong discovery depth and real-world clinical samples.
MapKure, LLC
MapKure, LLC is listed as a company partner, signaling collaboration in oncology research and biomarker-driven development. For Personalis, Inc., partnerships like this can extend the use of its platform into therapeutic programs and support precision medicine work across drug development.
SpringWorks Therapeutics
SpringWorks Therapeutics, Inc. is a disclosed partner that fits Personalis’ oncology focus: using sequencing data to help shape cancer trials and treatment guidance. In 2025, SpringWorks won U.S. FDA approval for Gomekli (mirdametinib), making genomic evidence even more relevant as it advances precision oncology programs.
Moores Cancer Center
Moores Cancer Center, an NCI-designated comprehensive cancer center at UC San Diego, gives Personalis access to clinical expertise, patient samples, and active oncology studies. The partnership also deepens Personalis’ reach in academic medicine, where 57 U.S. cancer centers hold comprehensive NCI status.
- Clinical expertise and samples
- Oncology research access
- Stronger academic medicine presence
Biopharma and research institutions
Biopharma and research institutions are core partners for Personalis, Inc. They provide repeat study work, patient samples, and sponsored projects that feed its precision oncology pipeline; in FY2024, Personalis reported revenue of about $77 million, showing how partner-led demand still anchors the model.
- Biopharma funds recurring assay work
- Academia supplies samples and studies
- Non-profits and government sponsor projects
Personalis’ Key Partnerships Power Its Precision Oncology Growth
Personalis’ key partnerships are mainly with biopharma, academic cancer centers, and research groups that fund studies, provide patient samples, and validate its sequencing platform. Mayo Clinic and Moores Cancer Center strengthen clinical evidence, while partners like SpringWorks Therapeutics, Inc. help tie Personalis, Inc. into precision-oncology trials.
| Partner type | Value to Personalis, Inc. |
|---|---|
| Biopharma | Sponsored assay work |
| Academic centers | Samples and validation |
| Research partners | Oncology pipeline access |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of Personalis, Inc. showing how its genomics platform creates value for customers and investors.
Customizable Excel Spreadsheet
Helps simplify Personalis, Inc.’s complex business model into a clear, editable one-page view.
Reference Sources
Provides a clear source trail for Personalis, Inc. data, making claims easier to verify and decisions more defensible.
Activities
Tumor and plasma sequencing
Personalis performs advanced sequencing on tissue and plasma, with NeXT Liquid Biopsy and ImmunoID Next showing its mix of blood-based and tissue-based analysis. In fiscal 2025, this work remained the core engine behind its platform outputs, supporting cancer profiling and minimal residual disease testing across clinical and research use cases.
Immune microenvironment analysis
Personalis’ NeXT Platform analyzes tumors and the surrounding immune microenvironment, helping users see how cancer cells and immune response interact. This capability supports biomarker discovery and treatment insight across oncology programs, and Personalis reported $62.9 million in revenue for 2024.
Bioinformatics and data analysis
Personalis, Inc. uses bioinformatics to turn sequencing output into usable clinical and discovery signals, including biomarkers and tracking markers from raw genomic data. This data layer supports both research and clinical workflows, and in Personalis, Inc.’s recent reporting, it remained tied to a high-value test menu built around tumor profiling and minimal residual disease detection.
Neoantigen prediction
Neoantigen prediction is a core, highly specialized activity for Personalis, Inc. using NeXT SHERPA and NeXT NEOPS to identify tumor-specific targets for immuno-oncology research. It feeds personalized vaccine and T-cell therapy design, helping turn large sequencing datasets into actionable antigen calls for discovery and biomarker work.
NeXT SHERPA and NeXT NEOPS
Supports vaccine and T-cell therapy
One of Personalis, Inc.’s most specialized functions
Assay development and validation
Personalis keeps refining NeXT Dx Test and NeXT Personal by running assay development and validation that fit both clinical and research use cases. That work matters because Personalis reported about $85 million in fiscal 2025 revenue, so keeping the platform validated helps protect demand across development stages.
- Supports clinical and research use cases.
- Keeps NeXT Dx and NeXT Personal current.
- Helps defend revenue near $85 million.
Personalis FY2025: Sequencing, Neoantigens, and $85M Revenue
Personalis, Inc. runs sequencing, bioinformatics, and neoantigen prediction to turn tissue and plasma samples into tumor profiles, MRD signals, and immuno-oncology targets. In fiscal 2025, these activities supported its clinical and research test menu, with about $85 million in revenue.
| Key activity | FY2025 data |
|---|---|
| Sequencing and analytics | Tissue and plasma profiling |
| Neoantigen prediction | NeXT SHERPA and NeXT NEOPS |
| Revenue | About $85 million |
Full Document Unlocks After Purchase
Business Model Canvas
The Personalis, Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what’s displayed is a real section of the final file. Once you buy, you’ll get the same complete, professionally formatted document, ready to use right away.
Resources
NeXT Platform
NeXT Platform is Personalis, Inc.'s core asset: it links sequencing, bioinformatics analysis, and immune profiling in one system, and it supports the NeXT Dx and other product lines. In 2025, that platform remained the base for clinical and research workflow scale, letting Personalis turn one technology stack into multiple revenue streams.
ACE platform
ACE turns one platform into 3 clinical uses: neoantigen prediction, biomarker identification, and drug target selection. That broadens Personalis, Inc. beyond a single test and supports both research and therapeutic programs.
Proprietary algorithms
Personalis relies on proprietary algorithms for biomarker calling, plasma analysis, and neoantigen prediction, which helps turn sequencing data into usable clinical signals. In a genomics market with dozens of competitors, this software layer is a core differentiator, especially as Personalis kept funding R&D to improve accuracy and scale.
Scientific and technical team
Personalis, Inc. relies on a scientific and technical team with deep cancer genomics, sequencing, and data science skills. That human expertise drives assay design, result interpretation, and customer support, and it is also what helps the Company work with pharma and academic partners on complex studies.
- Assay design and validation
- Genomics and sequencing expertise
- Data analysis and interpretation
- Partner support for pharma and academia
Sequencing and analysis infrastructure
Sequencing and analysis infrastructure is a core key resource for Personalis, Inc. because it combines lab systems and computing power to process very small tissue and plasma samples at scale, supporting both clinical product delivery and research services. This setup lets Personalis run high-throughput genomic workflows on the same platform it uses for customer projects and internal R&D.
- Lab systems handle tiny tissue and plasma inputs.
- Computing supports large-scale sequence analysis.
- Shared infrastructure serves products and research.
Personalis 2025: One Platform, Three Clinical Uses
Personalis, Inc.’s key resources are its NeXT Platform, ACE, proprietary biomarker and neoantigen software, and a genomics team that supports assay design, analysis, and partner work. Together, these assets let one 2025 platform support 3 clinical uses and both product and research revenue streams.
| Resource | 2025 fact |
|---|---|
| NeXT Platform | Core stack for sequencing and analysis |
| ACE | 3 uses: neoantigen, biomarker, target selection |
| Team | Genomics, bioinformatics, lab expertise |
Value Propositions
Small-sample tumor profiling
Personalis can profile very small tissue or plasma samples, which matters when only tiny biopsies or low-volume blood draws are available. That expands genomic testing to hard cases where standard assays fail, helping more patients get actionable results even when tumor material is scarce.
Liquid biopsy capability
Personalis, Inc. uses NeXT Liquid Biopsy and NeXT Personal for plasma-based analysis, so clinicians can monitor tumor DNA without tissue biopsy. This supports non-invasive tracking and longitudinal follow-up, which is key for spotting recurrence and treatment response earlier across serial blood draws.
In Personalis, Inc. filings through 2025, this liquid biopsy use case sits at the center of its precision-oncology push and helps widen clinical utility beyond a single test result.
Composite biomarker guidance
NeXT Dx identifies composite biomarkers for treatment guidance, helping customers read complex genomic signals and turn them into clearer oncology action. In Personalis, Inc.'s 2025 business model, this value prop matters because cancer testing demand is tied to high-stakes treatment choices and faster, more precise decision-making.
Neoantigen prediction
Personalis, Inc. uses NeXT SHERPA and NeXT NEOPS to predict neoantigens, giving researchers a fast way to rank tumor mutations by immune relevance. That helps immunotherapy, vaccine design, and target discovery by focusing on the few variants most likely to drive T cell response.
- Ranks immune-relevant tumor targets
- Supports immunotherapy and vaccines
- Improves antigen prioritization
Drug target and biomarker discovery
Personalis’ ACE platform turns genomic data into biomarker calls and new drug target leads, which helps therapeutic teams focus R&D on the most actionable signals. It is especially useful in large oncology and immuno-oncology studies where sequencing can surface response and resistance markers fast.
- Converts genomic data into research output
- Supports biomarker and target selection
- Shortens discovery decisions for drug teams
Personalis: Low-Input Liquid Biopsy for Diagnosis and MRD Tracking
Personalis’ value proposition is high-sensitivity oncology profiling from scarce tissue or plasma, plus non-invasive MRD tracking in serial blood draws. In 2025 filings, that matters because its core products span 2 liquid-biopsy uses: diagnosis support and recurrence monitoring.
| Value | 2025 anchor |
|---|---|
| Sparse-sample profiling | 1 low-input workflow |
| Plasma monitoring | 2 liquid-biopsy products |
| Immunotherapy targeting | Neoantigen ranking for trials |
Customer Relationships
Strategic B2B collaboration
Personalis, Inc. builds strategic B2B ties with biopharma firms and research institutions, so customer relationships are long term and tied to each study. This project-based model encourages repeat use of its sequencing and analysis services as teams move from discovery to validation.
That setup fits its high-touch, recurring workflow with the same scientific partners, which can support multi-study contracts and deeper account retention.
Scientific account support
Personalis’ scientific account support helps customers choose the right assay and read complex data, which matters in oncology where even small calls can change treatment paths. This high-touch model fits its specialized testing and the need for deep technical guidance across advanced workflows and biomarker interpretation.
Co-development partnerships
Named partners point to co-development, not one-off sales, and let Personalis, Inc. tune assays to each program. That model fits its 2025-2026 pipeline work, where tighter assay fit can speed adoption in therapeutic development.
Research program continuity
Academic, non-profit, and government studies often move through discovery, validation, and analysis in one multi-phase program, so Personalis can stay embedded from start to finish. That continuity matters in a market where trust and sample handling drive repeat work, especially across complex oncology and immunology studies.
- One partner across all phases
- Better handoff control
- Stronger repeat-program ties
Clinical and translational engagement
Personalis, Inc. relies on tight clinical and translational ties for its 2 key products, NeXT Dx Test and NeXT Personal. These services need ongoing scientific coordination so research results can be turned into patient-facing or trial-facing use, which makes trust, accuracy, and turnaround reliability central.
- 2 clinical products need repeat coordination
- Trust and reliability drive adoption
Personalis Wins on Trust, Accuracy, and Fast Study Coordination
Personalis, Inc. keeps customer ties high-touch and study-based: 2 clinical products, NeXT Dx Test and NeXT Personal, need repeated scientific coordination across trials and translational work. That makes trust, accuracy, and turnaround reliability central, not just sales.
| Metric | Latest data |
|---|---|
| Clinical products | 2 |
| Relationship model | Long-term, project-based |
| Core driver | Repeat study coordination |
Channels
Direct enterprise sales
Personalis likely sells directly to biopharma and institutional buyers, which fits its high-touch genomics model: one custom assay deal can cover trial biomarker work, MRD, or immune profiling. Direct sales also let Company Name tune panels, turnaround times, and data formats to each customer’s study design, which is key in specialized genomics.
Clinical research collaborations
Clinical research collaborations are a key delivery channel for Personalis, Inc.: partnerships with Mayo Clinic and cancer centers open access to study programs and real-world validation. This channel matters for credibility and adoption, since every new trial site can turn into a referral path and proof point for clinical use.
Academic and government networks
Personalis, Inc. serves academic institutions, non-profits, and government entities, and these networks can win sponsored projects and shared research work. Public R&D budgets matter here too: the U.S. NIH budget was about $48 billion in fiscal 2025, supporting translational studies that can widen awareness of precision oncology.
Scientific publications and conferences
Scientific publications and conference abstracts are a key channel for Personalis, Inc. because technical buyers want peer-reviewed proof of assay performance, reproducibility, and clinical utility before they adopt a genomics platform. Conferences also put Personalis, Inc. in front of researchers, clinicians, and drug developers at the exact point where biomarker and MRD decisions are made.
- Build trust with peer-reviewed data
- Reach technical buyers at conferences
- Support adoption of complex assays
Corporate website and product pages
Personalis, Inc. uses its corporate site and product pages to show 3 core offers: NeXT Platform, ACE, and NeXT Dx Test. These pages explain use cases, help buyers assess fit, and drive inbound leads by letting prospects request contact and learn the platform before sales outreach.
- 3 public product lines
- Supports inbound lead capture
- Educates buyers on fit
Personalis Expands Reach Through Direct Sales and Research Networks
Personalis, Inc. relies on direct sales, trial partnerships, and research networks to reach biopharma, hospitals, and academic buyers. Peer-reviewed papers, conference talks, and its site push inbound leads for NeXT, ACE, and NeXT Dx Test.
| Channel | 2025 data |
|---|---|
| NIH-funded research | About $48 billion |
| Public product lines | 3 |
| Core reach | Biopharma, clinics, academia |
Customer Segments
Biopharmaceutical companies
Biopharmaceutical companies are Personalis’ core commercial customer group and likely its largest revenue segment. They use Personalis’ genomic data to speed drug development, find biomarkers, and support clinical trials across precision oncology and immunology programs.
Academic institutions
Academic institutions, especially universities and medical schools, use Personalis, Inc. platforms for cancer research, where they need high-depth sequencing, neoantigen analysis, and tumor profiling. This segment values scientific depth and close collaboration, which fits research teams that work on discovery programs and translational studies in oncology.
Non-profit organizations
Non-profit organizations fund mission-driven translational oncology work, and in 2025 the NIH alone had a budget of about $47.0 billion, a key pool that supports this kind of research. They may sponsor studies using Personalis technology to improve biomarker discovery and patient matching, especially in programs aimed at faster clinical impact.
Government entities
Government entities use Personalis, Inc.'s genomics tools for public health, cancer, and funded research programs, where high data quality and tight reporting matter most. In 2025, the company still focused on research-use oncology and immunogenomics work, so this segment fits agencies that need validated sequencing and reproducible study output.
- Public health and cancer studies
- Funded research programs
- Strict QC and reporting needs
Oncology clinical programs
Personalis, Inc. serves oncology clinical programs through NeXT Personal and NeXT Dx, which are built for tumor tracking and treatment guidance in real patient care. The main buyers are hospitals and cancer centers that use these tests to follow disease over time and help guide therapy choices.
- Clinical-facing oncology labs
- Hospitals and cancer centers
- Tumor tracking and treatment guidance
Personalis’ Growth Is Powered by Biopharma and NIH-Backed Genomics Demand
Personalis, Inc.'s customers are mainly biopharma companies, plus academic centers, nonprofits, government agencies, and oncology hospitals. In 2025, NIH funding was about $47.0 billion, supporting research that can use Personalis, Inc. genomics tools.
Clinical demand also comes from cancer centers using NeXT Personal and NeXT Dx for tumor tracking and treatment guidance.
| Customer group | Need | 2025 data |
|---|---|---|
| Biopharma | Biomarkers, trials | Core revenue base |
| NIH-backed research | Genomics, profiling | $47.0B budget |
Cost Structure
R&D spending
Personalis, Inc. treats R&D as a core fixed cost because assay development and platform upgrades drive products like NeXT SHERPA and ACE. In 2024, the Company reported about $41 million of R&D expense, showing how much cash goes into keeping its cancer genomics platform current.
Laboratory operations
Laboratory operations are a core variable cost for Personalis, Inc.: sequencing, plasma profiling, consumables, and sample handling all scale with test volume. As more tests run, these costs rise fast, but they also sit at the center of product delivery and revenue generation.
Bioinformatics infrastructure
Bioinformatics infrastructure is a major fixed cost for Personalis, Inc.: each whole-genome analysis can generate 100 GB+ of raw data, so the company must fund compute, cloud storage, and constant software upkeep. Those costs rise with sample volume but also support both research and clinical workflows, where speed, traceability, and data retention matter.
Specialized personnel
Specialized personnel are a core cost for Personalis, Inc.: scientists, laboratory staff, bioinformaticians, and commercial teams are needed to run complex precision-oncology testing and explain the results. These roles are expensive, but they also drive quality, turnaround time, and the technical edge that sets Company Name apart.
- High-cost talent, high-value output
- Lab and data expertise are essential
- Commercial teams support growth and adoption
Sales and collaboration support
Personalis, Inc. relies on enterprise sales and partner management, so each customer program can require long sales cycles, joint development, and hands-on support. That makes relationship management and admin spending a real cost line, not just a back-office task.
- Long enterprise sales cycles
- Joint development support
- Higher admin and relationship costs
Personalis Faces Heavy R&D Costs to Keep Its Platform Current
Personalis, Inc. has a heavy cost base: lab work, sequencing, bioinformatics, and expert staff all scale with test volume, while R&D stays a large fixed spend. In 2024, R&D was about $41 million, showing how much the Company Name must invest to keep its cancer genomics platform current.
| Cost driver | 2024 value |
|---|---|
| R&D | about $41 million |
Revenue Streams
Per-sample testing fees
Personalis, Inc. can charge per-sample testing fees on each tissue and plasma specimen processed through ImmunoID Next, NeXT Liquid Biopsy, and NeXT Personal. Revenue rises with sample volume, so more clinical and biopharma testing directly lifts the top line.
Clinical profiling revenue
Clinical profiling revenue comes from NeXT Dx, which can generate diagnostic-style fees when customers pay for genomic profiling and biomarker interpretation. In Personalis, Inc.’s 2025 reporting, this stream stayed tied to clinical and translational use, so each test can add higher-value, recurring sample revenue versus pure research work.
Research service contracts
Personalis, Inc. uses research service contracts to fund custom projects for biopharma, academic, and government clients, covering sequencing, analysis, and reporting. This model supports recurring project revenue because each study can expand into follow-on work as programs move from discovery to validation.
Biomarker and neoantigen programs
ACE, NeXT SHERPA, and NeXT NEOPS support Personalis, Inc.'s biomarker discovery and neoantigen prediction work, so customers can pay for custom drug discovery projects. In FY2025, this stream fits pharma R&D demand because it sells specialized analysis, not just test volume.
- Custom biomarker discovery
- Neoantigen prediction projects
- Drug discovery support
Partner collaboration fees
Partner collaboration fees at Personalis, Inc. usually come from named oncology deals that mix funded project work with milestone payments, so they can bring both one-off and repeat income. These collaborations also widen platform use in cancer testing and sample analysis, while lowering commercial risk versus pure direct sales.
- Milestone-linked fees
- Recurring service income
- Oncology platform adoption
Personalis Revenue Grows With More Testing and Clinical Volume
Personalis, Inc.’s revenue streams are mostly per-sample testing fees, clinical profiling fees, and funded research contracts, with oncology collaboration work adding milestone-linked income. In FY2025, growth still depended on sample volume and project mix, so more clinical and biopharma testing meant higher recurring revenue.
| Stream | Revenue driver |
|---|---|
| Testing | Per-sample fees |
| Clinical profiling | NeXT Dx fees |
| Research/collab | Projects, milestones |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.